Form 4: Lava Therapeutics CFO Acquires Stock Options
SEC Form 4 Filing
Fred M. Powell, CFO of LAVA Therapeutics N.V., reports the acquisition of stock options.
Summary
- Fred M. Powell, the Chief Financial Officer of LAVA Therapeutics N.V., filed a Form 4 with the SEC.
- The filing reports the acquisition of 124,700 share options on February 13, 2025, at an exercise price of $0.93.
- The options vest in 48 equal monthly installments starting March 13, 2025, contingent upon continued service with the company.
- Following the transaction, Powell directly owns 124,700 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The CFO's acquisition could be interpreted as a positive signal, but it's not definitively bullish.
Positives
- The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the biopharmaceutical industry.
Stakeholder Impact
- The acquisition of stock options by the CFO may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of the transaction: acquisition of share options. |
| 03/13/2025 | First vesting date for the acquired share options. |
| 03/12/2035 | Expiration date of the acquired share options. |
| 02/18/2025 | Date of the Form 4 filing. |
Keywords
LAVA Therapeutics, LVTX, Form 4, SEC Filing, Stock Options, Fred M. Powell, CFO, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.